Abstract
Secukinumab, a high-affinity fully human monoclonal immunoglobulin G 1K antibody that selectively binds to and inhibits interleukin-17A, improves the signs and symptoms of active ankylosing spondylitis (AS). This article presents the results of the 16-Week Efficacy and 2-Year Long-term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis trial [MEASURE 1; NCT01358175], which evaluated intravenous loading and maintenance dosing of secukinumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
